The Cigna Group

Valuation Analysis

About the Company

The Cigna Group en bref

The Cigna Group (CI) is currently trading at 243,76 € with a market capitalization of 64,5 Md €. The trailing P/E ratio stands at 11.17x, with a forward P/E of 8.35x. The 52-week range spans from 209,01 € to 295,74 €; the current price is 17.6% below the yearly high. Year-over-year revenue growth stands at +4.6%. The net profit margin stands at 2.26%.

💰 Dividende

The Cigna Group currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

24 analystes évaluent The Cigna Group (CI) au consensus : Acheter. L'objectif de cours moyen est de 297,15 €, soit un potentiel de +21.9% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 253,08 € à 349,07 €.

The Cigna Group : la thèse d'investissement en détail

The Cigna Group (CI) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 29.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 21.9% upside from current levels — analyst sentiment is firmly constructive. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue growth has slowed to just 4.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 2.26%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

Valorisation en contexte

With a PEG ratio of 0.87, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.5x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 8.35x is meaningfully below the trailing 11.17x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.9% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy The Cigna Group?

Compare top-rated brokers — low fees, trusted providers, fully regulated.